Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 15/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10614521 | 0.87 | FFAR2 (0.61) | FFAR2KMT2AMEN1LMNA | |
| SCHEMBL10614514 | 0.87 | FFAR2 (0.61) | FFAR2KMT2AMEN1LMNA | |
| SCHEMBL9862938 | 0.85 | FFAR2 (0.59) | FFAR2KMT2AMEN1LMNA | |
| SCHEMBL11400312 | 0.85 | FFAR2 (0.59) | FFAR2KMT2AMEN1LMNA | |
| SCHEMBL10607697 | 0.85 | FFAR2 (0.59) | FFAR2KMT2AMEN1LMNA | |
| SCHEMBL7168267 | 0.84 | KMT2A (0.52) | FFAR2KMT2AL3MBTL1MEN1 | |
| SCHEMBL5516974 | 0.83 | ESR1 (0.57) | FFAR2KMT2A | |
| SCHEMBL22838087 | 0.83 | KMT2A (0.55) | FFAR2KMT2AL3MBTL1MEN1LMNA | |
| SCHEMBL2422613 | 0.83 | ESR1 (0.57) | FFAR2KMT2A | |
| SCHEMBL5510967 | 0.83 | ESR1 (0.57) | FFAR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951663-B1 | (R)-ARYLKYLAMINO DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPÉ FARMACEUTICI S P A (IT) | 2016-07-20 | — | — | EP | disclosed |
| CN-103275094-B | (20S)-camptothecin derivatives and application thereof | INST PLANT PROTECTION IPP CAAS | 2015-07-08 | — | — | CN | disclosed |
| CN-101360706-B | (R) -arylalkylamino derivatives and pharmaceutical compositions thereof | DOMPE PHA R MA SPA RES & MFG | 2013-10-02 | — | — | CN | disclosed |
| CN-103275094-A | (20S)-camptothecin derivatives and application thereof | INST PLANT PROTECTION IPP CAAS | 2013-09-04 | — | — | CN | disclosed |
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8026367-B2 | (R)-arylalkylamino derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2011-09-27 | — | — | US | disclosed |
| US-20090124664-A1 | (R)-Arylalkylamino Derivatives and Pharmaceutical Compositions Containing Them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2009-05-14 | — | — | US | disclosed |
| CN-101360706-A | (R) -arylalkylamino derivatives and pharmaceutical compositions thereof | DOMPE PHA R MA SPA RES & MFG (IT) | 2009-02-04 | — | — | CN | disclosed |
| EP-1951663-A2 | (R)-ARYLKYLAMINO DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' pha.r.ma s.p.a. (IT) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007060215-A2 | (R)-ARYLKYLAMINO DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA S.P.A. (IT) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124664-A1 | (R)-Arylalkylamino Derivatives and Pharmaceutical Compositions Containing Them | C3AR1, C5AR1, CCR8 | FFAR2 362/4885KMT2A 4790/4885L3MBTL1 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.